LRRK2 signaling in neurodegeneration: two decades of progress.
LRRK2
cytoskeleton
glia
inflammation
kinase inhibition
vesicular pathways
Journal
Essays in biochemistry
ISSN: 1744-1358
Titre abrégé: Essays Biochem
Pays: England
ID NLM: 0043306
Informations de publication
Date de publication:
22 12 2021
22 12 2021
Historique:
received:
26
08
2021
revised:
13
11
2021
accepted:
23
11
2021
pubmed:
14
12
2021
medline:
8
4
2022
entrez:
13
12
2021
Statut:
ppublish
Résumé
Leucine-rich repeat kinase 2 (LRRK2) is a complex GTPase/kinase orchestrating cytoskeletal dynamics and multiple steps of the endolysosomal pathway through interaction with a host of partners and phosphorylation of a subset of Rab GTPases. Mutations in LRRK2 cause late-onset Parkinson's disease (PD) and common variants in the locus containing LRRK2 have been associated with sporadic PD, progressive supranuclear palsy as well as a number of inflammatory diseases. This review encompasses the major discoveries in the field of LRRK2 pathobiology, from the initial gene cloning to the latest progress in LRRK2 inhibition as a promising therapeutic approach to fight neurodegeneration.
Identifiants
pubmed: 34897411
pii: 230434
doi: 10.1042/EBC20210013
doi:
Substances chimiques
LRRK2 protein, human
EC 2.7.11.1
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
859-872Informations de copyright
© 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.